Remember when drugmakers were growth stocks? If you wanted to track down juicy yields, you were better served by turning to utility or financial stocks. Not anymore. You wouldn't believe the kind of fat payouts being generated by the major pharmaceutical companies.

Company

Dividend Yield

Johnson & Johnson (NYSE:JNJ)

2.5%

Bristol-Myers Squibb (NYSE:BMY)

3.8%

Pfizer (NYSE:PFE)

4.5%

Merck (NYSE:MRK)

2.8%

GlaxoSmithKline (NYSE:GSK)

3.7%

Eli Lilly (NYSE:LLY)

2.9%

Wyeth (NYSE:WYE)

2.4%

It's no surprise that three of those seven companies have made the cut in the Income Investor newsletter service. High income and recession-resistant stock plays? Yum.

Unfortunately, it hasn't been all dividends and dependability in the drug sector. Many key players have become market laggards. More importantly, we can't get two Fools to agree on the prospects of one of the industry's biggest stars: Johnson & Johnson.

Ryan Fuhrmann is bullish this week. Billy Fisher returns as our bear. Where do you stand when it comes to Johnson & Johnson? That's what this week's bout is all about.

Duel on!

Johnson & Johnson, Eli Lilly, and GlaxoSmithKline have been recommended to Income Investor newsletter subscribers. Want a prescription to find other consistent income producers? Take a 30-day trial to the newsletter -- for free. 

Longtime Fool contributor Rick Munarriz did use Johnson & Johnson baby shampoo as a toddler. At least that's how he remembers it. He does not own shares in any of the companies in this article. Pfizer is an Inside Value recommendation. The Fool has a disclosure policy.